ClinicalTrials.gg
Active, not recruitingNCT07626515Updated Nov 5, 2026

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

A Phase 1 interventional study of Enicepatide and Placebo in Healthy Participants, sponsored by Hoffmann-La Roche. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No evidence of active or chronic disease as determined by detailed medical and surgical history and the results of a physical examination, vital signs, 12 lead (ECG), or clinical laboratory tests
  • ≥23 kg/m\^2 at screening
  • Agreement to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • History of acute or chronic pancreatitis
  • History of gallbladder disease in the opinion of the investigator
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder
  • History or presence of an abnormal that is deemed clinically significant in the opinion of the investigator
  • Clinically significant abnormalities (as judged by the investigator) in laboratory test results
  • History or presence of clinically significant cardiovascular disease, renal disease, hepatic disease, gastrointestinal disease, hematological disease, immunological disease, neurological disease, endocrine disease, metabolic disease, pulmonary disease, or history of any of these diseases with renal, hepatic, or cardiopulmonary dysfunction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Enicepatide Dose 1

    Combination Product: Enicepatide

  • Experimental
    Enicepatide Dose 2

    Combination Product: Enicepatide

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Combination productEnicepatide

    Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.

    Also known as: RO7795068, CT-388, RG6640

  • Combination productPlacebo

    Participants will receive matching placebo via subcutaneous (SC) injection as per the schedule in the protocol.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events

    Time frame: Baseline to Safety Follow-Up (27 weeks)

  2. Number of Participants with Abnormal Clinical Laboratory Parameters as a Shift from Baseline to Maximum Postbaseline Severity Grade

    Time frame: Baseline to Safety Follow-Up (27 weeks)

  3. Change from Baseline in Pulse Rate

    Time frame: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

  4. Change from Baseline in Respiratory Rate

    Time frame: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

  5. Change from Baseline in Systolic Blood Pressure

    Time frame: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

  6. Change from Baseline in Diastolic Blood Pressure

    Time frame: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

  7. Change from Baseline in Body Temperature

    Time frame: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

Secondary outcomes

  1. Plasma Concentration of Enicepatide

    Time frame: At prespecified time points from Day 1 to Day 190

  2. Maximum Plasma Concentration Observed (Cmax) of Enicepatide

    Time frame: At prespecified time points from Day 1 to Day 190

  3. Time to Cmax (Tmax) of Enicepatide

    Time frame: At prespecified time points from Day 1 to Day 190

  4. Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUClast) of Enicepatide

    Time frame: At prespecified time points from Day 1 to Day 190

  5. Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Enicepatide

    Time frame: At prespecified time points from Day 1 to Day 190

  6. Absolute Change From Baseline in Body Weight

    Time frame: Baseline through Week 24

  7. Percent Change From Baseline in Body Weight

    Time frame: Baseline through Week 24

07

Study locations

1 site
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2027 → Apr 2027 and completion May 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 4, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Apr 8, 2027was May 2027
CompletionEst.
Apr 8, 2027was May 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Primary completion
May 14, 2027→Apr 8, 2027
Nov 5, 2026
Study completion
May 14, 2027→Apr 8, 2027
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion May 14, 2027→Apr 8, 2027
    Study completion May 14, 2027→Apr 8, 2027
    + 3 other changes: verification date, contact details and site details
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07626515
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jul 2, 2026
Primary completion
Apr 8, 2027 (estimated)
Completion
Apr 8, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enicepatide

Start the discussion